title: Improved results using Onyx glue for the treatment of persistent type 2 endoleak after endovascular aneurysm repair.
abstract: OBJECTIVE
  Persistent type 2 (PT2) endoleaks (present ≥ 6 months) after endovascular aneurysm repair are associated with adverse outcomes, and selective secondary intervention is indicated in those patients with an expanding aneurysm sac. This study evaluated the outcomes of secondary intervention for PT2.
  
  
  METHODS
  From 1999 to 2007, 136 patients who underwent endovascular aneurysm repair developed PT2 and comprised the study cohort. Primary end points included PT2 resolution (secondary interventional success) and survival, and were evaluated using multiple logistic regression and Kaplan-Meier analyses, respectively.
  
  
  RESULTS
  Fifty-one patients underwent a total of 68 secondary interventions for PT2 with expanding aneurysm sacs with a median postsecondary interventional follow-up of 13.7 months. Secondary interventions included 20 inferior mesenteric artery coil embolizations, 17 Onyx glue embolizations, 11 aneurysm sac coil embolizations, 10 non-Onyx glue embolizations, 7 lumbar artery coil embolizations, 2 open lumbar ligations, and 1 graft explant. The overall secondary interventional success rate was 43% (29 of 68). Onyx glue embolization was associated with a greater success rate when used as the initial secondary intervention (odds ratio, 59.61; 95% confidence interval, 4.78-742.73; P < .001). There was no difference in success between the different techniques when multiple secondary interventions were required. Five-year survival was 72% ± 0.08% and was unrelated to any of the secondary interventional techniques.
  
  
  CONCLUSIONS
  Secondary intervention for PT2 is associated with success in less than half of all cases. Onyx glue embolization was associated with greater long-term success when used as the initial secondary intervention.
authors.affiliation: Division of Vascular and Endovascular Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Abularrage
authors.forename: Virendra I
authors.initials: VI
authors.lastname: Patel
authors.forename: Mark F
authors.initials: MF
authors.lastname: Conrad
authors.forename: Eric B
authors.initials: EB
authors.lastname: Schneider
authors.forename: Richard P
authors.initials: RP
authors.lastname: Cambria
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kwolek
mesh_terms: D000368:Aged; D000783:Aneurysm / Q000401:mortality / Q000601:surgery*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects* / Q000401:mortality; D001900:Boston; D016009:Chi-Square Distribution; D004121:Dimethyl Sulfoxide / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D057867:Endoleak / Q000000981:diagnostic imaging / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D057510:Endovascular Procedures / Q000009:adverse effects* / Q000401:mortality; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D016017:Odds Ratio; D011145:Polyvinyls / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D012086:Reoperation; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013635:Tantalum / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C558446:Onyx 18; C450660:Onyx copolymer; D011145:Polyvinyls; D013635:Tantalum; D004121:Dimethyl Sulfoxide